leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   87 Trials   87 Trials   2462 News 


12345678910111213...3839»
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Trial completion date:  Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov) -  Jan 23, 2026   
    P2,  N=60, Active, not recruiting, 
    These findings support incorporating a short neoadjuvant "window" before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs. antagonist trajectories. Trial completion date: Dec 2025 --> Jun 2026
  • ||||||||||  medroxyprogesterone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
    Preclinical, Journal:  Progestin-suppressed in vitro fertilization cycles yield similar outcomes to traditional protocols in patients with diminished ovarian reserve. (Pubmed Central) -  Dec 31, 2025   
    In multivariable models, the treatment group was not associated with the likelihood of having an embryo available for transfer (odds ratio 1.26, 95% confidence interval 0.74-1.53) or clinical pregnancy (odds ratio 0.98, 95% confidence interval 0.50-1.95). The progestin-suppressed IVF protocol provides similar reproductive outcomes in patients with diminished ovarian reserve, with the advantages of fewer monitoring visits, reduced injections, and lower medication costs.
  • ||||||||||  sunitinib / Generic mfg.
    Trial completion date, Trial primary completion date:  Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) -  Dec 26, 2025   
    P2,  N=64, Active, not recruiting, 
    The progestin-suppressed IVF protocol provides similar reproductive outcomes in patients with diminished ovarian reserve, with the advantages of fewer monitoring visits, reduced injections, and lower medication costs. Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Journal:  Late-stage Tyrosine ortho-C(sp2)-H Alkenylation for Macrocyclic Peptide SuFEx Proximity Labeling and Targeted Degradation. (Pubmed Central) -  Dec 26, 2025   
    We further developed a covalent cyclic peptide-lysosome targeting chimera (CCP-TAC) that selectively degrades PD-L1, remodels the tumor immune microenvironment, and exhibits favorable biosafety in vivo. Together, these findings establish tyrosine-directed C?H functionalization as a versatile platform for multifunctional cyclic peptides, bridging synthetic methodology with therapeutic application and advancing peptide stapling, covalent labeling, and degrader technologies.
  • ||||||||||  Preclinical, Journal:  Combination Hormonal Drug Therapy Inhibits In (Pubmed Central) -  Dec 26, 2025   
    MHC I activity and DNA damage response were upregulated. This anti-hormonal drug regimen for AGCT merits prospective investigation.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
    Journal:  Cerebellar Hemangioblastoma Resection Complicated by Postoperative Vasogenic Edema in the Setting of Concurrent Immunotherapy Treatment. (Pubmed Central) -  Dec 24, 2025   
    Our patient's postoperative edema was successfully managed via decompressive laminectomy and placement of a ventriculoperitoneal shunt, with resolution of symptoms seen postoperatively and at the 12-week follow-up. Tumor surgeons should be advised that patients on chemotherapy and immunotherapy agents may be at higher risk of postoperative edema and an associated mass effect on the surrounding structures.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Journal:  Impact of sleep fragmentation and estradiol suppression on positive and negative affect: Results of an experimental model of menopause. (Pubmed Central) -  Dec 21, 2025   
    Our findings show that MT-related characteristics significantly disrupt both positive and negative affect, potentially underlying emergence of depressive symptoms during this reproductive stage. We observed differential effects on positive and negative affect, with sleep fragmentation having a greater effect on NA and estradiol and VMS having a greater effect on PA, suggesting benefit for tailoring interventions that target specific types of affect regulation.
  • ||||||||||  Journal:  Unresectable Desmoplastic Small Round Cell Tumor: A Case Report and Review of the Literature. (Pubmed Central) -  Dec 5, 2025   
    In patients with androgen receptor positivity, hormonal blockade with leuprolide and bicalutamide may be a therapeutic option, particularly in frail patients...DSRCT is a challenging and aggressive malignancy requiring a multidisciplinary and individualized approach. The combination of systemic therapy and local control measures remains critical for improving patient outcomes.
  • ||||||||||  goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
    Retrospective data, Journal, Adverse events:  Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer. (Pubmed Central) -  Nov 19, 2025   
    Although excess risks differed slightly between Black and White patients, overall differences were small. These findings highlight the need for monitoring and mitigation strategies for patients receiving ADT.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Observational data, P4 data, Journal:  Therapeutic impact of leuprorelin acetate on spinal and bulbar muscular atrophy: pre- and post-marketing observational study. (Pubmed Central) -  Nov 19, 2025   
    These findings highlight the value of leveraging patient registries and post-marketing real-world data to evaluate treatment efficacy in slowly progressive diseases, such as SBMA, where traditional randomized controlled trials are often limited by insufficient statistical power to detect therapeutic efficacy. They also underscore the need for innovative methodologies to assess post-approval drug performance, paving the way for improved clinical outcomes for neurodegenerative diseases.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
    Journal:  Relugolix in treatment of prostate cancer: a review. (Pubmed Central) -  Nov 17, 2025   
    Relugolix represents a significant advancement in ADT, offering a potent, oral alternative with a rapid onset of action, a superior cardiovascular safety profile, and improved testosterone recovery. It provides clinicians with a valuable option for treating advanced prostate cancer, particularly in patients with cardiovascular comorbidities.
  • ||||||||||  Preclinical, Journal:  Two cases of MACS due to PBMAH associated with an in vivo aberrant response to LHRH treated with leuprolide acetate. (Pubmed Central) -  Nov 6, 2025   
    In both patients, morning serum cortisol levels remained elevated following 1 mg dexamethasone suppression test (DST) and 4 mg intravenous DST, while basal adrenocorticotropic hormone (ACTH) levels were suppressed...The first case involved a 69-year-old woman who exhibited significant increases in cortisol in response to luteinizing hormone-releasing hormone (LHRH; +142%), vasopressin (+66%) and metoclopramide (+98%)...In patients with MACS who have an aberrant cortisol response following LHRH stimulation, the long-acting GnRH agonist leuprolide acetate can be used to suppress endogenous LH production and improve hypercortisolism. A greater increase in cortisol secretion following LHRH stimulation and small response to the other stimuli could potentially be predictive of a better response to treatment with leuprolide acetate.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., apalutamide / Generic mfg., docetaxel / Generic mfg.
    "The National Prostate Cancer Registry (ProNAT) by d-uo: Three-Year Tumor Data" (C / D (Confex)) -  Nov 5, 2025 - Abstract #DGHO2025DGHO_1321;    
    These insights were previously unavailable and will support further optimization of prostate cancer care. The project is ongoing.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
    Journal:  Self-assembled leuprolide-oleic acid nanoparticles encapsulating docetaxel for synergistic drug delivery. (Pubmed Central) -  Nov 2, 2025   
    Furthermore, confocal microscopy confirmed the cellular uptake of the nanoparticles in both PC-3 and RAW 264.7 macrophage cells. Based on these findings, LOND, simultaneously releasing LEU, DTX, and fatty acids (such as OA), provides a promising drug delivery platform for triple synergy in the treatment of prostate cancer.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Journal:  Optimization of aqueous remote loading of leuprolide in poly(lactic-co-glycolic acid) microspheres. (Pubmed Central) -  Nov 2, 2025   
    The drug loading and EE were not strongly affected by porosity once above 50?%. Hence, by applying the theoretical analysis as described here, drug loading and EE can be manipulated to optimal levels by first monitoring quasi-equilibrium binding isotherms, indicating the potential for both general translational remote loading of therapeutic peptides and future applications for peptides with limited aqueous solubility and for encapsulation on the small scale.
  • ||||||||||  Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    When Therapy Leaves a Mark: A Case of Ribociclib-Induced Vitiligo Reversed with Abemaciclib (Exhibit Hall) -  Oct 30, 2025 - Abstract #SABCS2025SABCS_2099;    
    This case contributes to the limited literature on CDK4/6 inhibitor-induced pigmentary changes. It underscores the need for clinical awareness of this rare toxicity and demonstrates that switching agents within the same drug class may offer symptom resolution without compromising cancer treatment.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
    Journal:  Adverse Cardiovascular Outcomes of Individuals Treated with Androgen Deprivation Therapy. (Pubmed Central) -  Oct 23, 2025   
    Relugolix was not associated with lower risk of MACE in our analysis. Strategies to optimize the cardiovascular management of patients receiving ADT are needed.
  • ||||||||||  Xtandi (enzalutamide) / Pfizer, Astellas, leuprolide acetate for depot suspension / Generic mfg.
    Journal:  Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. (Pubmed Central) -  Oct 22, 2025   
    P3
    Enzalutamide monotherapy was not superior to leuprolide alone in the analysis of overall survival. (Funded by Pfizer and Astellas Pharma; EMBARK ClinicalTrials.gov number, NCT02319837.).
  • ||||||||||  abiraterone acetate / Generic mfg.
    Syndrome of Mineralocorticoid Excess with Abiraterone Use (Exhibit Hall, Convention Center) -  Oct 18, 2025 - Abstract #KIDNEYWEEK2025KIDNEY_WEEK_4068;    
    Case Description A 72-year-old man with past medical history of metastatic prostate cancer on leuprolide and abiraterone and hypertension presented from his primary care clinic with routine labs with recurrent hypokalemia to 2.8...Potassium levels stabilized after 2 days, and patient was discharge on spironolactone 150 mg in addition to his prednisone...Additionally, mineralocorticoid antagonists can be used to treat hypertension and hypokalemia . Mineralocorticoid antagonist used to suppresses aldosterone while awaiting effects of prednisone therapy in reducing ACTH drive.
  • ||||||||||  Xtandi (enzalutamide) / Pfizer, Astellas
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov) -  Oct 16, 2025   
    P4,  N=10, Completed, 
    Mineralocorticoid antagonist used to suppresses aldosterone while awaiting effects of prednisone therapy in reducing ACTH drive. Recruiting --> Completed | N=228 --> 10 | Trial completion date: Mar 2028 --> Jul 2025 | Trial primary completion date: Mar 2028 --> Jul 2025
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
    Clinical, Retrospective data, Review, Journal, HEOR:  Relugolix's impact on endometriosis-associated pain and quality of life: a meta-analysis of EHP-30 outcomes. (Pubmed Central) -  Oct 15, 2025   
    Oral relugolix significantly improves EHP-30 pain domain scores and patient response rates in endometriosis, particularly when compared to placebo. It also positively impacts emotional well-being, social support, and self-image.
  • ||||||||||  Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
    Journal:  Relugolix in prostate cancer therapy: Clinical evidence and practical considerations. (Pubmed Central) -  Oct 6, 2025   
    It offers rapid and sustained testosterone suppression, potential cardiovascular benefits, and an alternative to injectable therapies. Long-term adherence, the use of combination treatments and related drug-drug interactions require further investigation.
  • ||||||||||  A CLINICAL TRIAL TO ASSESS THE SAFETY OF AHC01 FOR THE TREATMENT OF ACUTE ABNORMAL UTERINE BLEEDING () -  Oct 6, 2025 - Abstract #FIGO2025FIGO_2766;    
    Long-term adherence, the use of combination treatments and related drug-drug interactions require further investigation. Progesterone only contraceptives...Exclusion criteria: A prospective participant will not be eligible for enrolment if they meet any of the following exclusion criteria: Current use of tranexamic acid (eg Lysteda